Joshua S. Krumenacker
University of Texas Health Science Center at Houston
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joshua S. Krumenacker.
Proceedings of the National Academy of Sciences of the United States of America | 2008
Kalpana Mujoo; Vladislav G. Sharin; Nathan S. Bryan; Joshua S. Krumenacker; Courtney Sloan; Shanaz Parveen; Lubov E. Nikonoff; Alexander Y. Kots; Ferid Murad
Nitric oxide (NO) is involved in number of physiological and pathological events. Our previous studies demonstrated a differential expression of NO signaling components in mouse and human ES cells. Here, we demonstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentiation of ES cells into myocardial cells. Our results with mouse and human ES cells demonstrate an increase in Nkx2.5 and myosin light chain (MLC2) mRNA expression on exposure of cells to NO donors and a decrease in mRNA expression of both cardiac-specific genes with nonspecific NOS inhibitor and a concomitant increase and decrease in the mRNA levels of sGC α1 subunit. Although sGC activators alone exhibited an increase in mRNA expression of cardiac genes (MLC2 and Nkx2.5), robust inductions of mRNA and protein expression of marker genes were observed when NO donors and sGC activators were combined. Measurement of NO metabolites revealed an increase in the nitrite levels in the conditioned media and cell lysates on exposure of cells to the different concentrations of NO donors. cGMP analysis in undifferentiated stem cells revealed a lack of stimulation with NO donors. Differentiated cells however, acquired the ability to be stimulated by NO donors. Although, 3-(4-amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine (BAY 41-2272) alone was able to stimulate cGMP accumulation, the combination of NO donors and BAY 41-2272 stimulated cGMP levels more than either of the agents separately. These studies demonstrate that cGMP-mediated NO signaling plays an important role in the differentiation of ES cells into myocardial cells.
Molecular Pharmacology | 2011
Haifeng Zhu; Jessica Li; Fang Zheng; Emil Martin; Alexander Y. Kots; Joshua S. Krumenacker; Byung Kwon Choi; Ian E. McCutcheon; Norman W. Weisbrodt; Oliver Bögler; Ferid Murad; Ka Bian
The NO and cGMP signaling pathways are of broad physiological and pathological significance. We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human glioma tissues and cell lines with that of healthy control samples and demonstrated that sGC expression is significantly lower in glioma preparations. Our analysis of GEO databases (National Cancer Institute) further revealed a statistically significant reduction of sGC transcript levels in human glioma specimens. On the other hand, the expression levels of particulate (membrane) guanylyl cyclases (pGC) and cGMP-specific phosphodiesterase (PDE) were intact in the glioma cells that we have tested. Pharmacologically manipulating endogenous cGMP generation in glioma cells through either stimulating pGC by ANP/BNP, or blocking PDE by 3-isobutyl-1-methylxanthine/zaprinast caused significant inhibition of proliferation and colony formation of glioma cells. Genetically restoring sGC expression also correlated inversely with glioma cells growth. Orthotopic implantation of glioma cells transfected with an active mutant form of sGC (sGCα1β1Cys105) in athymic mice increased the survival time by 4-fold over the control. Histological analysis of xenografts overexpressing α1β1Cys105 sGC revealed changes in cellular architecture that resemble the morphology of normal cells. In addition, a decrease in angiogenesis contributed to glioma inhibition by sGC/cGMP therapy. Our study proposes the new concept that suppressed expression of sGC, a key enzyme in the NO/cGMP pathway, may be associated with an aggressive course of glioma. The sGC/cGMP signaling-targeted therapy may be a favorable alternative to chemotherapy and radiotherapy for glioma and perhaps other tumors.
BMC Pharmacology | 2005
Ferid Murad; Joshua S. Krumenacker; Mujoo Kalpana; Ks Madhusoodanan
We hypothesized that the fundamental role of nitric oxide and cyclic GMP in numerous physiological processes would suggest that these mediators also participate in stem cell proliferation and differentiation. Mouse and human (H9) embryonic stem cells were cultured under standard conditions for various periods (one to 15 days). The hanging drop method was utilized to induce differentiation of stem cells into various cellular lineages including myocardial, neuronal precursor, neuronal, astrocyte and oligodendrocytes.
Medical Science Monitor | 2001
Khalid A. Hanafy; Joshua S. Krumenacker; Ferid Murad
Brain Research Bulletin | 2004
Joshua S. Krumenacker; Khalid A. Hanafy; Ferid Murad
Nitric Oxide | 2006
Joshua S. Krumenacker; Shoji Katsuki; Alexander Kots; Ferid Murad
Proceedings of the National Academy of Sciences of the United States of America | 2001
Joshua S. Krumenacker; Salman M. Hyder; Ferid Murad
Molecular Genetics and Metabolism | 2006
Joshua S. Krumenacker; Ferid Murad
Proceedings of the National Academy of Sciences of the United States of America | 2000
Iraida Sharina; Joshua S. Krumenacker; Emil Martin; Ferid Murad
American Journal of Physiology-cell Physiology | 2005
Joshua S. Krumenacker; Alexander Y. Kots; Ferid Murad